[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Imagenebio Inc (IMA)

Imagenebio Inc (IMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,360
  • Shares Outstanding, K 10,654
  • Annual Sales, $ 800 K
  • Annual Income, $ -45,350 K
  • EBIT $ -51 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.73
  • Price/Sales 78.71
  • Price/Cash Flow N/A
  • Price/Book 0.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.99
  • Number of Estimates 3
  • High Estimate $-0.62
  • Low Estimate $-1.36
  • Prior Year $-0.72
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +17.29%
on 04/09/26
6.64 -20.33%
on 04/13/26
+0.72 (+15.75%)
since 04/08/26
3-Month
3.94 +34.26%
on 03/27/26
7.55 -29.93%
on 02/09/26
-1.62 (-23.44%)
since 02/06/26
52-Week
3.94 +34.26%
on 03/27/26
18.00 -70.61%
on 07/28/25
-7.67 (-59.18%)
since 05/08/25

Most Recent Stories

More News
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update...

IMA : 5.29 (-10.49%)
ImageneBio Announces $30 Million Private Placement

Private placement led by Coastlands Capital with participation from additional new and existing investors   Proceeds will support further development of IMG-007 in alopecia areata and late-stage...

IMA : 5.29 (-10.49%)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the...

IMA : 5.29 (-10.49%)
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December...

IMA : 5.29 (-10.49%)
ImageneBio to Participate in Leerink Global Healthcare Conference

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings...

IMA : 5.29 (-10.49%)
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive...

MLTX : 17.06 (-0.81%)
IMA : 5.29 (-10.49%)
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced...

IMA : 5.29 (-10.49%)
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological,...

IMA : 5.29 (-10.49%)
ImageneBio CFO Resignation Announced

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

IMA : 5.29 (-10.49%)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune...

IMA : 5.29 (-10.49%)

Business Summary

Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly...

See More

Key Turning Points

3rd Resistance Point 6.32
2nd Resistance Point 6.11
1st Resistance Point 5.70
Last Price 5.29
1st Support Level 5.08
2nd Support Level 4.87
3rd Support Level 4.46

See More

52-Week High 18.00
Fibonacci 61.8% 12.63
Fibonacci 50% 10.97
Fibonacci 38.2% 9.31
Last Price 5.29
52-Week Low 3.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.